Vasodilator Therapies in the Treatment of Acute Heart Failure
- 200 Downloads
Purpose of Review
Vasodilators are commonly recommended to treat acute heart failure (AHF), yet they are infrequently used. This review aims to evaluate the clinical utility of traditional, historical, and novel vasodilators in the treatment of AHF.
No traditional vasodilator (i.e., nitroglycerin) therapy definitely improves short- or long-term outcomes. Despite repeated efforts to develop new pharmacologic treatments, no novel therapy outperforms traditional management. At the present time, we continue to recommend traditional vasodilators, such as nitroglycerin.
The use of select vasodilators in the treatment of AHF improves hemodynamics and provides short-term relief; however, data regarding long-term benefits is lacking.
KeywordsAcute heart failure Vasodilator(s)
Compliance with Ethical Standards
Conflict of Interest
Daniel B. Holt Jr. declares no conflicts of interest.
Peter S. Pang reports grants from AHA, NHLBI, and AHRQ during the conduct of the study; grants from Roche; personal fees, non-financial support, and other from Novartis, BMS, and Trevena; personal fees and non-financial support from Baxter; and other from Orthodiagnostics and Edwards outside the submitted work, and associate editor for JACC Heart failure, and Editorial board for the Journal of Cardiac Failure.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. https://doi.org/10.1161/CIR.0000000000000558.CrossRefGoogle Scholar
- 2.Heidenreich PA, Albert NM, Allen LA, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.CrossRefGoogle Scholar
- 5.Wong YW, Fonarow GC, Mi X, Peacock WF IV, Mills RM, Curtis LH, et al. Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the acute decompensated heart failure registry emergency module (ADHERE-EM). Am Heart J. 2013;166(2):349–56. https://doi.org/10.1016/j.ahj.2013.05.014.CrossRefGoogle Scholar
- 6.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefGoogle Scholar
- 7.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128.CrossRefGoogle Scholar
- 8.Acute Heart Failure Syndromes. Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. American College of Emergency Medicine, May, 2007. https://www.acep.org/patient-care/clinical-policies/acute-heart-failure-syndromes/#sm.00000ixjak0swgfqwwnufn8dak1b0.
- 10.Collins SP, Storrow AB. Acute heart failure. In: Tintinalli JE, Stapczynski JS, Ma OJ, et al., editors. Tintinalli’s emergency medicine: a comprehensive study guide. New York: McGraw-Hill Education; 2016.Google Scholar
- 11.Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med. 2001;2(Suppl 2):S7–S12.Google Scholar
- 14.Verma SP, Silke B, Hussain M, Nelson GIC, Reynolds GW, Richmond A, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol. 1987;10(1):38–46.CrossRefGoogle Scholar
- 16.Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531–40 Erratum in: JAMA 2002 Aug 7;288(5):577.Google Scholar
- 20.Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS, American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007;49(5):627–69.CrossRefGoogle Scholar
- 21.Long B, Koyfman A, Gottlieb M. Management of heart failure in the emergency department setting: an evidence-based review of the literature. J Emerg Med. 2018. https://doi.org/10.1016/j.jemermed.2018.08.002.
- 27.Peacock WF, Chandra A, Char D, Collins S, der Sahakian G, Ding L, et al. Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO). Am Heart J. 2014;167(4):529–36. https://doi.org/10.1016/j.ahj.2013.12.023.CrossRefGoogle Scholar
- 28.• Pang PS, Butler J, Collins SP, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017;38(30):2364–73. https://doi.org/10.1093/eurheartj/ehx196. This randomized controlled trial investigated the safety and efficacy of an angiotensin II type I receptor ligand, for use in the treatment of acute heart failure.CrossRefGoogle Scholar
- 29.Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (biased ligand of the angiotensin receptor study in acute heart failure). JACC Heart Fail. 2015;3(3):193–201. https://doi.org/10.1016/j.jchf.2014.09.008.CrossRefGoogle Scholar
- 30.• Packer M, O'Connor C, McMurray JJV, et al. TRUE-AHF Investigators. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376(20):1956–64. https://doi.org/10.1056/NEJMoa1601895. This randomized controlled trial investigated ularitide, an analogue of the natural vasodilator urodilantin, in the treatment of acute heart failure.CrossRefGoogle Scholar
- 32.Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823–32.Google Scholar
- 33.• Teerlink JR, Cotter G, Davison BA, et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39. https://doi.org/10.1016/S0140-6736(12)61855-8. This randomized controlled trial investigated the effects of serelaxin, a recombinant of human relaxin-2, responsible for hemodynamic changes in pregnancy, in the treatment of acute heart failure.CrossRefGoogle Scholar
- 37.RELAXin in acute heart failure-2 - RELAX-AHF-2. American College of Cardiology, May 8, 2017. https://www.acc.org/latest-in-cardiology/clinical-trials/2017/05/07/16/09/relax-ahf-2.
- 38.Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12(11):1253–60. https://doi.org/10.1093/eurjhf/hfq133.CrossRefGoogle Scholar
- 39.Novartis heart drug portfolio hit by failed serelaxin study. Reuters, March 22, 2017 http://www.reuters.com/article/ us-novartis-heart-idUSKBN16T0QG.